Doctor of Optometry Program year 2025 Reported 2019–2025 Source: CMS Open Payments, 2026 publication

Daniel Owens

Ophthalmology Lombard, IL Doctor of Optometry

NPI 1750544250 CMS profile 260891

130 S Main St, Suite 303, Lombard, IL 60148

Open in the dashboard

General payments

$342,737

47 records reported · program years 2019–2025

Research payments

$0

Paid to them · None reported · program years 2019–2025

Ownership & investment interest

$0

None reported

Through program year 2025, Daniel Owens of Lombard, IL is reported in the CMS Open Payments database as having received $342,737 across 47 general payments and $0 in research payments paid to them.

No combined total General, research and ownership are kept apart. Each is reported under its own rules, and ownership is not money that moved at all but the value of a stake held. A meal, a clinical trial grant and a shareholding do not add up to anything meaningful, so this site does not add them.

General payments for this record sit in the 98th percentile of Ophthalmology profiles with reported payments. Percentile describes the distribution, not the conduct.

By program year

7 rows
Year Kind Relative to this record's peak year Amount Records
2025 General $135 4
2024 General $258 2
2023 General $183,198 18
2022 General $158,334 14
2021 General $631 6
2020 General $17 1
2019 General $165 2

Beside peers

Year by year, beside peers General payments · among profiles paid that year
  • Daniel Owens
  • Ophthalmology median
  • Middle half of Ophthalmology
  • National median

In program year 2025, general payments to Daniel Owens were reported at $135. Among 13,034 Ophthalmology profiles paid that year, the median was $384 and the middle half received between $136 and $917.

Show as a table
Year Daniel Owens Ophthalmology median Middle half National median
2019 $165 $258 $104–$655 $163
2020 $17 $126 $45–$321 $114
2021 $631 $205 $76–$534 $132
2022 $158,334 $266 $100–$678 $149
2023 $183,198 $308 $117–$745 $160
2024 $258 $340 $127–$846 $164
2025 $135 $384 $136–$917 $169

Breakdown

Who paid General payments · program years 2019–2025
  1. Baxter Healthcare $341,238 26 payments
  2. AbbVie, Inc. $612 6 payments
  3. Regeneron Healthcare Solutions, Inc. $230 2 payments
  4. Allergan Inc. $157 3 payments
  5. Cardinal Health 110, LLC $150 1 payment
  6. Welch Allyn $150 1 payment
  7. Alcon Vision LLC $43 1 payment
  8. Sight Sciences, Inc. $36 1 payment
  9. Astellas Pharma US Inc $32 1 payment
  10. Amgen Inc. $24 1 payment
  11. Other $66 4 payments

Every payment, record by record

What the payments were for General payments · program years 2019–2025
  1. Consulting Fee $341,863 28 payments
  2. Food and Beverage $725 18 payments
  3. Honoraria $150 1 payment
Products named General payments · program years 2019–2025
  1. Hillrom - RetinaVue 700 Imager $341,238 26 payments
  2. Hillrom - RetinaVue Network $341,238 26 payments
  3. OZURDEX $522 4 payments
  4. RetinaVue Network $150 1 payment
  5. EYLEA HD $122 1 payment
  6. EYLEA $108 1 payment
  7. UNITY $43 1 payment
  8. OMNI SURGICAL SYSTEM $36 1 payment
  9. SION SURGICAL INSTRUMENT $36 1 payment
  10. Izervay $32 1 payment
  11. Other $138 11 payments

A payment can name more than one product, so these amounts overlap and do not add up to the general-payment figure.

Prescribing to Medicare patients

Part D · data year 2024 · 3 drugs

Part D claims

68

Median for Ophthalmology: 891

Drug cost

$1,796

Median for Ophthalmology: $68,233

Branded share of claims

0%

Median for Ophthalmology: 29.7%

Drugs this doctor was counted under in Medicare Part D 2024, by drug cost
Drug Type Relative to their largest Claims Drug cost
Prednisolone Acetate Generic 28 $1,405
Ketorolac Tromethamine Generic 18 $281
Latanoprost Generic 22 $109

Drug cost is what was paid for the drugs at the pharmacy — by Medicare, the patient and others — and is not money to the prescriber. Medicare Part D only: drugs dispensed to Medicare beneficiaries. A drug with fewer than 11 claims for this prescriber is not published, so a missing drug does not mean zero. The medians are for the 18,260 Part D prescribers listed as Ophthalmology; they describe a distribution and say nothing about conduct.

Billing to Medicare

Part B · data year 2024 · 26 billing codes

Paid by Medicare

$686,744

Of which drugs: $549,411

Medicare patients

391

Average age 79

Services billed

9,940

239 women, 152 men among their patients

Share of this provider's Medicare patients with each condition
Condition among their Medicare patients Relative to the most common Share of patients
High blood pressure 75%
Arthritis 44%
Diabetes 37%
Ischemic heart disease 32%
Chronic kidney disease 30%
Atrial fibrillation 24%
Heart failure 23%
Cancer 21%
Drugs given in the clinic that this provider billed Medicare Part B for
Drug given in the clinic Where Patients Services Paid by Medicare
Injection, aflibercept, 1 mg J0178 Office 69 432 $278,693
Injection, faricimab-svoa, 0.1 mg J2777 Office 42 6,480 $176,415
Injection, bevacizumab, 10 mg J9035 Office 49 153 $8,480

Medicare Part B only: services billed to Medicare. Rows covering fewer than 11 beneficiaries are not published. Only drugs given in the clinic are itemised here; the rest of what this provider billed is in the total above.

Records

47 reported

Every payment, record by record

Date, company, amount, what it was for and the product named — filter by year, kind and company, or download as CSV.

Other Ophthalmology in Illinois

Related records

What this means

U.S. law requires drug and medical device manufacturers to report payments and transfers of value they make to physicians and teaching hospitals. The Centers for Medicare & Medicaid Services publishes that record each year. This page shows what was reported about this person, and nothing else.

An ownership interest is different from the other two. It is not a payment: it is a stake — shares, options, a partnership holding — that a physician or an immediate family member held in a manufacturer during that year. The figure shown is what the stake was reported to be worth.

Research payments frequently pass through a clinician to the institution running a trial, and rarely represent personal income. They should be read differently from general payments.

Provenance

Source: CMS Open Payments · through program year 2025

Data current to program year 2025, from CMS's 2026 publication.

We reproduce what manufacturers reported. We do not verify, edit or correct the underlying records.

A payment record is not evidence of wrongdoing. Financial relationships between industry and medicine are legal, common and often necessary for research. Who Paid My Doc reports what was disclosed; it does not judge it.

Who Paid My Doc is independent and is not affiliated with, endorsed by or sponsored by CMS or any U.S. government agency. It is not a consumer reporting agency and this is not a consumer report; do not use it for decisions covered by the Fair Credit Reporting Act.

How to dispute or correct a record